The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | Debate on the best first-line treatment for unmutated CLL: opinions from across the Atlantic
Susan O’Brien, MD from UC Irvine Health, Orange County, CA reviews the case discussion session, ‘California vs. Germany CLL’, which took place during the International Conference on Malignant Lymphoma (ICML) 2017, Lugano, Switzerland. Dr O’Brien describes how the opinions on chronic lymphocytic leukemia (CLL) treatment approaches compared between European and American experts, providing examples of clinical data discussed during the session. While it was agreed that FCR is the best first-line treatment for patients with mutated CLL, opinions were split regarding the best treatment for unmutated CLL. Dr O’Brien shares her opinions on the matter and those of her fellow discussants.
This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.
